Hexarelin — Potent Second-Generation GHSR-1a Agonist Research Peptide

Hexarelin (His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH₂) is a synthetic second-generation hexapeptide GHRP and one of the most potent GHSR-1a agonists available in the growth hormone peptides research toolkit. Structurally similar to GHRP-6 but incorporating a 2-methyl substitution on the D-tryptophan residue, Hexarelin demonstrates significantly enhanced GHSR-1a binding affinity and GH-releasing potency compared to first-generation GHRPs. Researchers in pituitary pharmacology, cardiovascular biology, and GH axis research use this hexarelin research peptide both as a high-potency GHSR-1a reference agonist and as a tool compound for studying non-GHSR cardiovascular signaling through CD36 receptor interactions. Furthermore, this dual receptor activity profile makes Hexarelin one of the most mechanistically rich GH secretagogue research compounds available.

Mechanism of Action

Hexarelin exerts its biological effects through two distinct receptor-mediated pathways, making it mechanistically unique among synthetic GHRPs.

At GHSR-1a, Hexarelin binds with high affinity and activates Gq-protein coupled phospholipase C signaling. This generates IP3 and DAG second messengers, elevates intracellular calcium, and activates PKC. As a result, it potently stimulates GH secretion from anterior pituitary somatotroph cells. Its 2-methyl substitution on D-Trp enhances receptor binding stability and resistance to enzymatic degradation, contributing to its superior GH-releasing potency compared to GHRP-6 in comparative studies.

At CD36, a scavenger receptor expressed in cardiac tissue, macrophages, and endothelial cells, Hexarelin activates signaling cascades independent of GHSR-1a. This CD36-mediated pathway drives cardioprotective effects including reduced cardiac fibrosis, improved ventricular function, and protection against ischemia-reperfusion injury in preclinical models. Consequently, Hexarelin uniquely bridges GH secretagogue research and cardiovascular biology through two separate receptor systems. Therefore, researchers studying GH-independent cardioprotective peptide mechanisms specifically require Hexarelin over other GHRPs.

Hexarelin vs. First-Generation GHRPs

Hexarelin and GHRP-6 share the same hexapeptide backbone and GHSR-1a target. However, they differ in several key ways that determine their respective research applications.

Hexarelin achieves greater GH-releasing potency at equivalent molar doses due to its enhanced GHSR-1a binding affinity from the 2-methyl D-Trp substitution. Additionally, Hexarelin activates CD36 receptor signaling — a mechanism entirely absent in GHRP-6. Furthermore, at high doses, Hexarelin stimulates cortisol and prolactin secretion more prominently than selective second-generation GHRPs such as Ipamorelin. Consequently, researchers choose Hexarelin specifically when studying high-potency GHSR-1a pharmacology, CD36-mediated cardiovascular signaling, or comparative GH secretagogue potency studies. They choose Ipamorelin when receptor selectivity and HPA axis neutrality are the priority.

Key Research Applications

Researchers actively use Hexarelin across multiple GH and cardiovascular research domains. Specifically, it supports:

• High-potency GHSR-1a pharmacology — Studies requiring a maximally efficacious GHSR-1a reference agonist for receptor binding characterization, GH secretory ceiling determinations, and full dose-response curve generation in pituitary cell systems.
• GH secretagogue potency comparisons — Comparative experimental designs benchmarking Hexarelin against GHRP-6 and Ipamorelin to characterize the relationship between GHSR-1a binding affinity, structural modifications, and GH secretory output.
• CD36 receptor research — Studies investigating CD36-mediated cardioprotective signaling, cardiac fibrosis inhibition, and ischemia-reperfusion protection using Hexarelin as a selective CD36-activating research tool.
• Cardiovascular protection research — Preclinical models examining Hexarelin-mediated improvements in ventricular function, cardiac remodeling inhibition, and myocardial protection through combined GHSR-1a and CD36 pathway activation.
• Pituitary somatotroph biology — Research examining maximum GH pulse amplitude, somatotroph secretory capacity, and receptor desensitization kinetics under high-potency GHSR-1a stimulation with Hexarelin.
• Synergistic dual-secretagogue research — Experimental protocols pairing Hexarelin with GHRH analogues such as CJC-1295 or Sermorelin to study synergistic GH amplification through simultaneous GHSR-1a and GHRHR co-activation at high GH secretory potency.

Peptide Profile

Reconstitution Guidelines

Reconstitute Hexarelin with sterile bacteriostatic water. Add solvent slowly along the inner vial wall and gently swirl until the lyophilized powder fully dissolves. Do not shake or vortex. For a 5mg vial, researchers typically add 1–2ml of solvent to achieve a suitable working concentration for their assay system. Furthermore, prepare single-use aliquots before storage at 4°C to minimize repeated freeze-thaw exposure across multi-session experimental protocols.

Storage Conditions

Store lyophilized Hexarelin vials at −20°C, protected from direct light and moisture. Additionally, keep vials sealed until the point of reconstitution. Once reconstituted, maintain at 4°C and use within 28–30 days. Avoid repeated freeze-thaw cycles to preserve GHSR-1a and CD36 binding affinity and overall peptide integrity throughout the study duration.

For research use only. Not intended for human or veterinary administration. This product is not a drug, supplement, or food product.